Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

2(28.6%)

Phase 4

1(14.3%)

N/A

1(14.3%)

7Total

Phase 2(3)

Phase 3(2)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01512472Phase 4Terminated

Firmagon (Degarelix) Intermittent Therapy

Role: lead

NCT02936258Not ApplicableUnknown

PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures

Role: lead

NCT00553878Phase 2Completed

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

Role: lead

NCT02656563Phase 2Withdrawn

Radium 223 Following Intermittent ADT

Role: lead

NCT01354171Phase 3Unknown

Active Surveillance Magnetic Resonance Imaging Study

Role: lead

NCT00554086Phase 2Completed

Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.

Role: lead

NCT00236002Phase 3Terminated

Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

Role: lead

All 7 trials loaded